“A comprehensive study recently published in the Journal of the American Medical Association, rebuts a hypothesized link among common medications for attention deficithyperactivity disorder (ADHD) and a subsequent risk of heart attack, stroke, or sudden heart death.
The study, which compared groups of 150,000 adults who were prescribed ADHD drugs with 300,000 adults who did not receive the medications, suggests for the first time there is no evidence of a significant association between ADHD drugs and cardiovascular risks. Specifically, the study found the absolute risk associated with ADHD medication was one heart related adverse event for every 5000 person-years of drug therapy.”
“. . . An editorial accompanying the JAMA study explains previous research suggested widely used ADHD medications, such as psychostimulants and atomoxetine (brand name Strattera), increased blood pressure and heart rates among adults. The editorial notes since increased blood pressure and heart rates normally are clinically associated with an increase in cardiovascular risks, the use of routine ADHD medications became an understandable, widely hypothesized concern for physicians and ADHD patients.
“. . . However, Shaw writes (and we quote): ‘the (current) study provides no evidence to support routine obtaining of electrocardiograms before starting treatment, certainly insofar as this recommendation was driven by concerns about serious cardiovascular events’ (end of quote). Overall, Shaw concludes among adult ADHD patients (and we quote): ‘Now there is solid evidence – perhaps even some heartening news – that physicians can use to address concerns about cardiovascular risk’ (end of quote).